IMMERVISION
Immervision , the Montreal-based leader in wide-angle intelligent vision, introduces JOYCE , the first humanoid robot developed by the computer vision community to help machines gain human-like perception and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005563/en/
Watch the video: https://vimeo.com/458617443
The purpose of JOYCE is to further advance computer vision technologies by inviting the community to help JOYCE gain a better understanding of her environment by upgrading her optics, sensors and AI algorithms.
To support the realization of this complex task, Immervision is also unveiling the JOYCE Development Kit for engineers and AI developers. This “JOYCE IN A BOX” development kit is equipped with three ultra-wide-angle panomorph cameras calibrated to give 2D hemispheric, 3D stereoscopic hemispheric or full 360 x 360 spherical capture and viewing of the environment. It uses data-In-picture technology so that each of her video frames can be enriched with data from a wide array of sensors providing contextual information to AI and neural networks, computer vision and SLAM algorithms to help increase her visual perception.
Moreover, JOYCE will be streaming live so that people can, not only follow the evolution of her capabilities, but also look through her eyes while she travels around the world, skydives, visits a business conference or a computer vision lab.
JOYCE stems from the Immervision InnovationLab which mission is to accelerate the emergence of new innovative solutions and help build the next generation of intelligent vision systems for a wide range of industry devices.
“At Immervision, we strongly believe in the value of bringing together the computer vision community to break down the silos that are slowing the innovation cycle. Instead, let’s push forward the boundaries of machine perception through cross-pollination. We believe that JOYCE will help develop extremely innovative solutions to resolve complex industry challenges,” said Pascale Nini, President and CEO of Immervision.
Potential use cases include:
- Enhance the performance of smart home devices such as vacuum cleaners, lighting systems and home appliances.
- Improve optics technologies to ensure driver safety in assisted driving and autonomous cars.
- Improve fire fighters ability to detect people and objects over trees and see through smoke.
- Improve medical diagnostics to better identify cancer tumors or other conditions on a CT scan.
- Help identify early signs of crop diseases, and many more.
To follow JOYCE’s progress and collaboration within the community, visit her at JOYCE.VISION and follow her on her social channels.
About Immervision
Immervision enables intelligent vision in any device. Our Deep Seeing technology and renowned experts in wide-angle optical design and image processing enable smart devices with superhuman eyes to capture high quality visual and contextual data. We invent, customise and license wide-angle lenses and imaging software technology for AI, machine vision and user applications, from capture to display, in the mobile, automotive, robotics, security, and other industrial and consumer product industries. www.immervision.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release
Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release
Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release
New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
